In today’s environment, CMOs are often required to make sharper, more strategic trade-offs much earlier than before. Dr Peter Hovstadius, CMO of Lipum AB and the Swedish Association of the Pharmaceutical Industry (LIF), shares how CMOs balance between early clinical study design, scientific rigor and limited financing.
